Literature DB >> 17044195

Spindle cell tumors of the pleura: differential diagnosis.

Monica Rdzanek1, Raoul Fresco, Harvey I Pass, Michele Carbone.   

Abstract

Spindle cell tumors that arise in or metastasize to the pleura must be thoroughly evaluated to arrive at a definitive diagnosis. Malignant mesothelioma is the most common tumor arising in the pleura, but metastatic tumors to the pleura occur more frequently. Additionally, many tumors arising in the lung and surrounding tissues involve the pleura. It is crucial to arrive at a correct diagnosis since many of these neoplasms show different prognoses and require varying treatment modalities. Sarcomatoid malignant mesothelioma is a rare tumor that arises in the pleura, and can be confused with numerous tumors arising in or metastasizing to the pleura, including synovial sarcoma, metastatic sarcomatoid carcinoma, metastatic melanoma, thymoma, renal cell carcinoma, localized fibrous tumor, leiomyosarcoma, and other types of sarcoma. Desmoplastic malignant mesothelioma is a fibrous sarcomatoid variant of malignant mesothelioma, and is occasionally mistaken for chronic fibrous pleurisy. Here, we review morphological, clinical, histological, immunohistochemical, ultrastructural, and molecular methods that aid in the diagnosis of spindle cell tumors of the pleura, and we provide specific examples of patients in which this multi-modal approach proved to be helpful.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17044195     DOI: 10.1053/j.semdp.2006.06.002

Source DB:  PubMed          Journal:  Semin Diagn Pathol        ISSN: 0740-2570            Impact factor:   3.464


  6 in total

1.  GATA3 is a useful immunohistochemical marker for distinguishing sarcomatoid malignant mesothelioma from lung sarcomatoid carcinoma and organizing pleuritis.

Authors:  Zheng Hua Piao; Xin Cheng Zhou; Jia Yi Chen
Journal:  Virchows Arch       Date:  2021-02-11       Impact factor: 4.064

2.  The immunohistochemical characterization of sarcomatoid malignant mesothelioma of the pleura.

Authors:  Lucian R Chirieac; Geraldine S Pinkus; Jack L Pinkus; John Godleski; David J Sugarbaker; Joseph M Corson
Journal:  Am J Cancer Res       Date:  2010-09-30       Impact factor: 6.166

3.  Increased efficacy of doxorubicin delivered in multifunctional microparticles for mesothelioma therapy.

Authors:  Jedd M Hillegass; Steven R Blumen; Kai Cheng; Maximilian B MacPherson; Vlada Alexeeva; Sherrill A Lathrop; Stacie L Beuschel; Jeremy L Steinbacher; Kelly J Butnor; Maria E Ramos-Niño; Arti Shukla; Ted A James; Daniel J Weiss; Douglas J Taatjes; Harvey I Pass; Michele Carbone; Christopher C Landry; Brooke T Mossman
Journal:  Int J Cancer       Date:  2010-11-03       Impact factor: 7.396

Review 4.  The pathological and molecular diagnosis of malignant pleural mesothelioma: a literature review.

Authors:  Greta Alì; Rossella Bruno; Gabriella Fontanini
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

5.  Inflammation precedes the development of human malignant mesotheliomas in a SCID mouse xenograft model.

Authors:  Jedd M Hillegass; Arti Shukla; Sherrill A Lathrop; Maximilian B MacPherson; Stacie L Beuschel; Kelly J Butnor; Joseph R Testa; Harvey I Pass; Michele Carbone; Chad Steele; Brooke T Mossman
Journal:  Ann N Y Acad Sci       Date:  2010-08       Impact factor: 5.691

6.  Tumors that mimic asbestos-related mesothelioma: time to consider a genetics-based tumor registry?

Authors:  Brent D Kerger; Robert C James; David A Galbraith
Journal:  Front Genet       Date:  2014-05-30       Impact factor: 4.599

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.